

Form PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. 14730		Serial No. 09/868,813	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				Applicant Tracy Ann Willson, et al.			
				Filing Date June 21, 2001		Group <del>Unassigned</del> 1647	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AK	WO 98/20023	5/14/98	PCT			
	AL	WO 98/14574	4/9/98	PCT			
	AM	WO 97/35978	10/2/97	PCT			
	AN	WO 99/03993	1/28/99	PCT			
	AO	WO 99/03994	1/28/99	PCT			
	AP	WO 99/40946	8/19/99	PCT			
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AQ	Kamura, T., et al. (1998) "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 Repeat, and ankyrin repeat families", <u>Genes Dev</u> 12(24): 3872-3881					
BL	AR	Zhang, J. G., et al. (1999) "The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation", <u>Proc Natl Acad Sci USA</u> 96(5):2071-2076					
BL	AS	Alexander, W.S., et al. (1999) "Suppressors of cytokine signaling (Socs): negative regulators of signal transduction", <u>J. Leukoc Biol</u> 66(4): 588-592					
BL	AT	Alexander, W.S., et al. (1999) "SOCS 1 Is a Critical Inhibitor of Interferon $\gamma$ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine" <u>Cell</u> 98(5): 597-608					
BL	AU	Bousquet, C., et al. (1999) "Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor" <u>J. Clin Invest</u> 104(9): 1277-1285					
EXAMINER				DATE CONSIDERED			
<small>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.</small>							

Form PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEAtty. Docket No.  
14730Serial No.  
09/868,813LIST OF PRIOR ART  
CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Tracy Ann Willson, et al.Filing Date  
June 21, 2001Group  
Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>PK</i>	AK	WO 98/20023	5/14/98	PCT				
	AL	WO 98/14574	4/9/98	PCT				
	AM	WO 97/35978	10/2/97	PCT				
	AN	WO 99/03993	1/28/99	PCT				
	AO	WO 99/03994	1/28/99	PCT				
	AP	WO 99/40946	8/19/99	PCT				

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>PK</i>	AQ	Kamura, T., et al. (1998) "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 Repeat, and ankyrin repeat families", <u>Genes Dev</u> 12(24): 3872-3881						
	AR	Zhang, J. G., et al. (1999) "The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation", <u>Proc Natl Acad Sci USA</u> 96(5):2071-2076						
	AS	Alexander, W.S., et al. (1999) "Suppressors of cytokine signaling (Socs): negative regulators of signal transduction", <u>J. Leukoc Biol</u> 66(4): 588-592						
	AT	Alexander, W.S., et al. (1999) "SOCS 1 Is a Critical Inhibitor of Interferon $\gamma$ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine" <u>Cell</u> 98(5): 597-608						
	AU	Bousquet, C., et al. (1999) "Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor" <u>J. Clin Invest</u> 104(9): 1277-1285						

EXAMINER

DATE CONSIDERED

11/12/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.

Form PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. 14730		Serial No. 09/868,813	
LIST OF PRIOR ART CITED BY APPLICANT				Applicant Tracy Ann Willson, et al.			
(Use several sheets if necessary)				Filing Date June 21, 2001		Group Unassigned 1647	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
BL	AK	WO 98/20023	5/14/98	PCT			
	AL	WO 98/14574	4/9/98	PCT			
	AM	WO 97/35978	10/2/97	PCT			
	AN	WO 99/03993	1/28/99	PCT			
	AO	WO 99/03994	1/28/99	PCT			
	AP	WO 99/40946	8/19/99	PCT			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BL	AQ	Kamura, T., et al. (1998) "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 Repeat, and ankyrin repeat families", <u>Genes Dev</u> 12(24): 3872-3881					
BL	AR	Zhang, J. G., et al. (1999) "The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation", <u>Proc Natl Acad Sci USA</u> 96(5):2071-2076					
BL	AS	Alexander, W.S., et al. (1999) "Suppressors of cytokine signaling (Socs): negative regulators of signal transduction", <u>J. Leukoc Biol</u> 66(4): 588-592					
BL	AT	Alexander, W.S., et al. (1999) "SOCS 1 Is a Critical Inhibitor of Interferon $\gamma$ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine" <u>Cell</u> 98(5): 597-608					
BL	AU	Bousquet, C., et al. (1999) "Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor" <u>J. Clin Invest</u> 104(9): 1277-1285					
EXAMINER				DATE CONSIDERED 11/12/04			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.							